Abstract
The second wave of COVID-19, which began around 11 February 2021, has hit India very hard with the daily cases reaching nearly triple the first peak value as on April 19, 2021. The epidemic evolution in India is quite complex due to regional inhomogeneities and the spread of several coronavirus mutants. In this paper, we characterize the virus spread in the ongoing second wave in India and its states until April 19, 2021, and also study the dynamical evolution of the epidemic from the beginning of the outbreak. Variations in the effective reproduction number (Rt) are taken as quantifiable measures of the virus transmissibility. Rt value for every state, including those with large rural populations, has value greater than the self-sustaining threshold of 1. An exponential fit on recent data also shows that the infection rate is much higher than the first wave. Subsequently, characteristics of the COVID-19 spread are analyzed regionwise, by estimating test positivity rates (TPRs) and case fatality rates (CFRs). Very high TPR values for several states present an alarming situation. CFR values are lower than those in the first wave but recently showing signs of increase as healthcare systems become over-stretched with the surge in infections. Preliminary estimates with a classical epidemiological model suggest that the peak for the second wave could occur around mid-May 2021 with daily count exceeding 0.4 million. The study strongly suggests that an effective administrative intervention is needed to arrest the rapid growth of the epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This material is based partly upon work supported by a SERB MATRICS project SERB/F/847/2020-2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work does not need any approval of the IRB/oversight body.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
rajeshr{at}iitk.ac.in
aryans{at}iitk.ac.in
mkv{at}iitk.ac.in
This version considers COVID-19 data until April 19, 2021.
Data Availability
The data included in the study are publicly available.
